Alzheimer’s disease (AD) requires objective biomarkers to differentiate it from other causes of cognitive decline and to guide timely care. At Southern Medical Supplies Limited (SMSL), we offer a comprehensive AD work-up spanning CSF and blood-based biomarkers—including Aβ1-42/Aβ1-40 ratio, total tau, phospho-tau (p-Tau181/p-Tau217), and neurofilament light (NfL)—with optional APOE genotyping and targeted panels for early-onset familial AD (e.g., APP, PSEN1, PSEN2) where clinically indicated, plus adjunct testing to exclude reversible etiologies (thyroid dysfunction, B12 deficiency, infection, autoimmune encephalitis antibodies). Our portfolio includes ELISA, chemiluminescent/automated immunoassays, and molecular assays sourced from a broad network of trusted global partners—EUROIMMUN, Ansh Labs, Randox, Streck, Bio-Rad, Abbott, Roche, Siemens Healthineers, Qiagen, bioMérieux, Cepheid, Werfen, Globe Scientific, ELGA LabWater, LW Scientific, Sebia, LTA SRL, Acrobiotech, MAKOL Innovacion Medica, Rayto Life and Analytical Sciences, Diazyme, Hardy’s Diagnostics, and Teco Diagnostics—delivering the analytical sensitivity, specificity, and reproducibility clinicians need for early detection, differential diagnosis, risk stratification, and longitudinal monitoring in Alzheimer’s disease.